Individual susceptibility to cancer from environmental agents may be influenced by polymorphic metabolic genes such as CYP1A1. The CYP1A1 gene contains four major polymorphisms identified to date. A modern nomenclature system, used with other genes, is presented to clarify the identity of these polymorphisms. The various CYP1A1 alleles exhibit population frequencies that depend on ethnicity. The association of these alleles with cancer at several sites has also been found to depend on racial or ethnic origin of the study population. Statistical considerations, such as the need for large studies when the power to detect a rare polymorphism is low, and ethnic differences in genetic linkage disequilibrium are among possible reasons for ethnic-specific effects on cancer susceptibility related to metabolic gene polymorphisms. New efforts to determine population frequencies of such polymorphisms are essential for future research in this area.
Introduction
Individual differences in susceptibility may be very important in determining the actual risk to human health from environmental toxicants. Even cancers with well-known environmental risk factors, such as smoking-induced lung cancer, have important genetic components in their etiology (1) . In susceptible individuals a much lower level of exposure could produce the same adverse health effects as that seen with higher exposure in the average or non-susceptible population.
Individual susceptibility to cancer may be partly explained by genetic variability in metabolic activities related to phase I and phase II detoxification enzyme pathways. Polymorphisms in these metabolic susceptibility genes, which have been extensively discussed in several recent reviews, as well as being the subject of an IARC monograph (2) , have been linked to increased risk of cancer in several case-control studies. One feature of the published literature in this area that has received less attention than may be warranted is the fact that in many instances the associations between a particular genetic risk factor and cancer appears to be race or ethnicity specific. Table  I shows some examples of metabolic gene polymorphisms related to cancer susceptibility based on results from a recent meta-analysis of the literature (3). Significant positive associations (lower 95% confidence interval of the odds ratio Ͼ 1.0) are indicated by a plus sign and absence of significant association is indicated by a minus sign. As can be seen, the majority of the examples analyzed show ethnic specificity. The purpose of this commentary is to discuss this issue in relation *Abbreviations: AHH, aromatic hydrocarbon hydroxylase; RFLP, restriction fragment length polymorphism.
to one particular gene, CYP1A1, and to propose some general principles related to the investigation of cancer susceptibility genes taking into account some concepts of population genetics.
The cytochrome P450 enzymes, which represent a large multigene family with differing substrate specificities, are important in phase I detoxification reactions (4, 5) . The CYP1A1 gene product, aromatic hydrocarbon hydroxylase (AHH*), catalyzes the first oxidative step in the metabolism of polycyclic aromatic hydrocarbons, such as those found in tobacco smoke, to carcinogens. This gene is induced by exposure to agents such as dioxin, benzo[a]pyrene and other aromatic hydrocarbons. The results of extensive research have clarified many of the molecular mechanisms by which inducing agents act on the gene (6) (7) (8) . Polymorphisms in the catalytic or regulatory domains of the CYP1A1, aryl hydrocarbon receptor (AHR) or ARNT genes could be expected to have important consequences for the function of this system and could lead to changes in sensitivity to the effects of exposure to carcinogenic hydrocarbons.
CYP1A1 polymorphisms
At the present time the CYP1A1 gene is known to contain four important sequence polymorphisms (9-13), one of which is specific to people of African descent (12) . These polymorphic alleles have been named according to widely differing nomenclature systems used by various authors, resulting in a considerable potential for confusion. Systematic attempts to produce a standard nomenclature for metabolic gene polymorphisms have been made for the NAT genes (14) , as well as CYP2D6 and related genes (15) . Cascorbi et al. applied this approach to CYP1A1 (13) and a general review covering all the metabolic gene polymorphisms is currently in press (16).
For CYP1A1 each of the polymorphisms is given a number in order of publication, which follows the symbol*. Thus CYP1A1*1 is the wild-type. An MspI restriction fragment length polymorphism (RFLP) in the 3Ј-non-coding region of CYP1A1 (CYP1A1*2) is closely linked in Asians and less so in Caucasians with a second polymorphism in exon 7 of the gene (CYP1A1*3) (11, 17) . This point mutation polymorphism is in a region of the gene that codes for part of the catalytic site of the gene product AHH, and the presence of this polymorphism confers a significant 3-fold effect on the catalytic activity of the AHH enzyme in Asians (18, 19) . Because of the linkage between these two polymorphisms, Cascorbi et al. have suggested calling them *2A and *2B. (13) . However, in our studies of CYP1A1 genotype in people of African descent (20) we have found that the two polymorphisms are not associated with each other and therefore should be given separate numbers. In fact, although the *2 allele is fairly common, the *3 polymorphism is rare in African-Americans, and very rare (none detected so far) in Africans. The Africanspecific RFLP (CYP1A1*4) is located in intron 7, outside the coding region but upstream of the polyadenylation site (12) . 
Lung -ϩ -a ϩ, significant positive association with lower 95% confidence interval Ͼ 1.00; -, no significant association; NA, not available. An additional polymorphism designated CYP1A1*5 has recently been detected in exon 7 (13) .
It is possible that *2, which is located outside the coding region of the gene, serves as a marker for the functional *3 polymorphism in Asians and Caucasians. However, it is unlikely that this is true in people of African descent. In fact, we have observed no evidence for any 'linkage' between any of the three polymorphisms (*2, *3 and *4) in Black populations (20) .
Population genetics of CYP1A1 genotypes
Human CYP1A1 genotype frequencies, like those for other genes (21) (22) (23) , show large inter-ethnic differences, especially between the major racial groups (24) . Race-specific frequencies for the *2, *3 and *4 alleles derived from the literature are shown in Table II . Good estimates for the frequency of the *1 allele cannot be obtained from these published studies, since in most cases only one polymorphism was determined at a time. Therefore, some of the homozygous 'normal' genotypes with respect to *2, for example, may actually be heterozygous for *3, etc. We have genotyped Ͼ500 individuals for each of the polymorphisms simultaneously. Table III shows the results for five ethnic populations. The data for allele frequencies of the three polymorphisms are very similar to those from the literature, but in Table III one can also find a good estimate of the true frequency of the 'wild-type' allele *1. The African and Latino populations sampled were small, but it is interesting to note that even in this small sample persons who identified themselves as Hispanic exhibit a frequency of the *2 and *3 alleles midway between those of Caucasians and Asians, as might be expected from admixture between these groups. No examples of the *4 allele have been found in Caucasians or Asians. The frequency of the *3 polymorphism in African-Americans is consistent with a 20% admixture rate between Africans and Caucasians, which is comparable with other previous studies of African-American admixture (25) . The data imply that both the *3 and *4 mutations occurred after divergence of Caucasians and Asians from African populations.
CYP1A1 polymorphisms and cancer
In addition to differences in population frequencies, the various CYP1A1 gene polymorphisms have been found to be differentially associated with increased risk of several cancers (including lung, breast and colon) in different specific ethnic groups (9,17,26-30). There are several possible explanations for why a particular genotype might be differentially associated with cancer in different ethnic populations. A statistical consideration based on differences in allele frequencies known to exist between populations may explain certain apparent differences found in small studies. For example, both the CYP1A1*2 and *3 polymorphisms have been associated with lung and bladder cancer in Japanese (9,31) but not in Caucasian (17, 27) or African-American populations (26) . Because of the much smaller frequency of these polymorphisms in the Caucasian population, the association found in Japanese would require a case-control study of at least 500-1000 cases to have sufficient power to be detected in Caucasians. Although one recent report did show an association between CYP1A1*2 and lung cancer in Caucasians (32) , most of the studies that have been published in Caucasians have not been large enough to compensate for the very low population frequency of this allele in Caucasians compared with Asians. The extreme case for this scenario would be if an allele is completely missing in certain ethnic groups. For CYP1A1 this is true for the *4 polymorphism in Caucasians and Asians. This allele has been associated with adenocarcinoma of the lung (and possibly the prostate) in African-Americans (28, 33) , although this association was not confirmed by another group (34) .
The second explanation may be related to differences in linkage or genetic associations between alleles in different populations. This has been observed for CYP1A1, where people of African descent show no linkage between the *2 and *3 alleles, in contrast to Caucasians and Asians. Our finding of an association between the CYP1A1*2/CYP1A1*2 homozygous genotype and breast cancer in African-American but not in Caucasian women (29) is probably due to differences in linkage of the CYP1A1*2 allele to other loci in these two populations. This conclusion is based on the idea that it is unlikely that the *2 polymorphism, which occurs outside any coding or regulatory region of the gene, has any direct effect on gene function or disease incidence by itself. In Caucasians, as discussed above, this RFLP probably serves as a marker for the *3 polymorphism in exon 7 of the gene, but in AfricanAmericans it is instead probably linked to some other locus with a different functional activity that is somehow related to the effect on breast cancer. These other putative loci could include any of a large number of cancer susceptibility genes distributed throughout the genome. It is important to note that such genes may also be in linkage disequilibrium with various metabolic gene polymorphisms in certain populations and not in others. It is also possible that different ethnic groups have different modifiers of gene function, not necessarily linked to specific polymorphisms. In this case, a complex ethnic-specific pattern of gene function and disease association would be observed, including differential effects of the polymorphisms.
Finally it may be possible that certain alleles actually have different functions in different populations. This possibility seems less likely than the other two, since it is difficult to conceive of a mechanism that would cause such differences other than differences related to linkage with other genes whose functions impact on the target gene product. There is no evidence for this phenomenon in the CYP1A1 gene.
Conclusions
Given the ethnic-specific effects that have been established for CYP1A1 (as well as certain other metabolic genes) it seems clear that before any conclusions can be made regarding the effects of any gene polymorphism on cancer a clear and statistically satisfactory picture of the normal genotype frequencies must be established for each ethnic and regional population 1331 group under study. Ethnicity is often difficult to define, even for the three major racial groupings. It is not clear, for example, that Norwegians and Greeks will necessarily share a single 'Caucasian' genotype frequency. The same is true for Asians. For example, the frequency of the CYP2C19 polymorphism differs between two ethnic Chinese populations (35) . An even more striking example is the population frequency of the CYP2A6*3 (CYP2A6v2) allele (36) . While this allele has a frequency of 28% among Japanese, it is present at only 6% in Taiwanese. The frequency among the English is 7%, but it is completely absent in Finland (36) . The situation for Latin Americans is also quite complex, given the high degree of inter-racial admixture. In Africa, where genetic diversity is quite high, knowledge of specific tribal or regional origin of the population under study is critical. In our study of CYP1A1 genotypes from Mali the population sample included individuals from 17 different ethnic tribal groups. Figure 1 shows the frequency of the CYP1A1*4 allele (African-specific) among the five major ethnic groupings. In addition to genotype frequencies, investigation is needed on ethnic-specific differences in gene and allele linkages and, if possible, differences in the functional implications of different genotypes on the gene products.
As the study of genetic risk factors for cancer progresses, research in molecular epidemiology is beginning to interface with population genetics. One of the first points that workers in the field must deal with is that allele frequencies are not randomly distributed throughout the human population, but generally follow patterns of ethnic, racial and geographic specificities. Ignoring this fact can lead to major errors in the interpretation of case-control studies designed to evaluate the association of a genetic polymorphism with cancer risk or linkage between two or more polymorphisms. As investigations become more precise, the classical definitions of race and ethnicity tend to become less useful. Instead, the emerging paradigm indicates that for such studies to be meaningful very careful matching between cases and controls must be done with regard to ethnic and/or geographic origin. Knowledge of population dynamics and demographics, for example the degree of admixture between migrant and host populations and the socio-economic and other factors that influence this, will become crucial to this effort. 
